5 days ago
Evercore ISI Sticks to Its Buy Rating for Intellia Therapeutics (NTLA)
Evercore ISI analyst Liisa Bayko maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) yesterday and set a price target of $48.00. The company's shares closed yesterday at $7.45.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Bayko is a 4-star analyst with an average return of 5.9% and a 40.98% success rate. Bayko covers the Healthcare sector, focusing on stocks such as Altimmune, Vertex Pharmaceuticals, and Intellia Therapeutics.
In addition to Evercore ISI, Intellia Therapeutics also received a Buy from JonesTrading's Debanjana Chatterjee in a report issued today. However, yesterday, J.P. Morgan maintained a Hold rating on Intellia Therapeutics (NASDAQ: NTLA).
The company has a one-year high of $28.18 and a one-year low of $5.90. Currently, Intellia Therapeutics has an average volume of 3.83M.
